Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?

Key Takeaways Gilead will report Q3 2025 results on Oct. 30, with sales and EPS estimates of $7.46B and $2.15.HIV portfolio strength from Biktarvy, Descovy, and new approval Yeztugo is driving top-line growth.Cell Therapy sales likely declined amid competition, while Trodelvy and Livdelzi demand stayed strong.Biotech bigwig Gilead Sciences, Inc. (GILD)   is scheduled to report third-quarter 2025 results on Oct. 30, after market close. The Zacks Consensus Estimate for sales and earnings is pegged at $7.46 bi ...